Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Asieris Pharmaceuticals (Shanghai) Co., Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, indicating separate examination assignments.
MCMILLIAN, KARA RENITA is the busiest examiner, with 1 pending action. Counsel should adapt prosecution responses to each examiner’s record rather than use one uniform approach.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCMILLIAN, KARA RENITA | 1 | 30.9% | +37.9% |
| LEE, SIN J | 1 | 68.8% | +25.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17757801 | PHARMACEUTICAL COMPOSITION CONTAINING NITROXOLINE, NITROXOLINE TABLET, PREPARATION METHOD THEREFOR AND USE THEREOF | LEE, SIN J | 73d overdue |
| 18561801 | USE OF 5-NITRO-8-HYDROXYQUINOLINE | MCMILLIAN, KARA RENITA | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18561801 | USE OF 5-NITRO-8-HYDROXYQUINOLINE | MCMILLIAN, KARA RENITA | 1623 | §103 | Final Rejection | — | Pending | Nov 17, 2023 |
| 17757801 | PHARMACEUTICAL COMPOSITION CONTAINING NITROXOLINE, NITROXOLINE TABLET, PREPARATION METHOD THEREFOR AND USE THEREOF | LEE, SIN J | 1613 | §103Other | Non-Final OA | 73d overdue | Pending | Jun 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAsieris Pharmaceuticals (Shanghai) Co., Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kara Renita Mcmillian has the most, with 1 of Asieris Pharmaceuticals (Shanghai) Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
